References:

• Role of NKG2D and its ligands in cancer immunotherapy.

  Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z.
  Am J Cancer Res. 2019;9(10):2064-2078. Published 2019 Oct 1.

• The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

  Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ.
  Blood. 2005 Nov 15;106(10):3666-72. Epub 2005 Jul 26.

• Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide.

  Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, Graham CH.
  Cancer Res. 2008 Jun 15;68(12):4746-53.

• NKG2D-independent suppression of T cell proliferation by H60 and MICA.

  Kriegeskorte AK, Gebhardt FE, Porcellini S, Schiemann M, Stemberger C, Franz TJ, Huster KM, Carayannopoulos LN, Yokoyama WM, Colonna M, Siccardi AG, Bauer S, Busch DH.
  Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11805-10. Epub 2005 Aug 9.